Motherwort Safety: Cardiac Interactions and Pregnancy

Motherwort is usually described as gentle, and by the standards of medicinal plants it probably is. But gentleness is not the whole safety question. This herb has a peculiar problem: the people most drawn to it are the people for whom it is least straightforward. Someone with palpitations is disproportionately likely to be taking a beta-blocker, a rate-limiting calcium channel blocker, an antiarrhythmic, digoxin, or an anticoagulant. Someone reassured by the word "motherwort" is disproportionately likely to be pregnant or newly delivered — and pregnancy is a firm contraindication.

That mismatch between audience and profile is what this page is about. It sets out the two safety issues that actually matter — cardiac and sedative drug interactions and pregnancy — and labels each honestly as theoretical, preclinical, or documented, because there is a real difference and pretending otherwise misleads in both directions.


Table of Contents

  1. Safety Summary
  2. Pregnancy: A Firm Contraindication
  3. Why the Name Misleads About Pregnancy
  4. Breastfeeding
  5. Why This Population Is the Wrong One
  6. Beta-Blockers and Other Rate-Slowing Drugs
  7. Digoxin and Antiarrhythmic Drugs
  8. Blood-Pressure Medication
  9. Sedatives, Alcohol and Other Calming Herbs
  10. Antiplatelet and Anticoagulant Drugs
  11. Direct Side Effects
  12. Product Quality and Species Substitution
  13. Who Should Avoid It Entirely
  14. How to Raise It With Your Doctor
  15. Evidence Tiers at a Glance
  16. Key Research Papers
  17. Connections

Safety Summary

The short version, before the detail:

One framing point that shapes everything below. Motherwort has an acceptable traditional safety record — it is registered in the European Union as a traditional herbal medicinal product, a status that requires documented long-standing use without serious harm. It does not have a modern pharmacovigilance dataset, systematic interaction studies, or human pharmacokinetic data. "No documented cases" therefore means something much weaker than it sounds: nobody is systematically looking. Where the consequence of an interaction is an arrhythmia or a bleed, the asymmetry favours caution.

Back to Table of Contents

Pregnancy: A Firm Contraindication

Do not take motherwort during pregnancy. This is the single firmest statement on any motherwort page on this site, and it does not depend on modern research at all — it comes out of the tradition's own account of the plant.

Motherwort was classed by European herbalists as an emmenagogue — a plant used to bring on a delayed or scanty menstrual period — and as a uterine stimulant, given after childbirth to help the womb contract back down. Both are uterine-activating roles. A plant selected precisely because it can nudge the uterus into activity has no acceptable risk-benefit case during a pregnancy you intend to keep. Standard herbal safety references and European regulatory documentation both list pregnancy as a contraindication, and this is the reason given.

Notice the shape of the argument. It does not claim there is trial evidence that motherwort causes miscarriage — there is no such trial, and there never will be, because it would be unethical to run. It claims something more defensible: a herb whose traditional purpose includes uterine stimulation, with no human safety data in pregnancy, cannot be recommended in pregnancy. Absence of evidence is not reassurance when the outcome at stake is a pregnancy. Very large doses have also been associated historically with uterine bleeding, which points in the same direction.

The same logic extends to two adjacent situations:

If you are pregnant and have palpitations, breathlessness, chest discomfort, or severe anxiety, those symptoms deserve assessment in their own right. Pregnancy changes cardiac physiology considerably — blood volume and heart rate both rise — and while most palpitations in pregnancy turn out benign, some presentations need attention and pregnancy is not a good time to guess. Speak to your midwife or doctor.

Back to Table of Contents

Why the Name Misleads About Pregnancy

This deserves its own section because the failure mode is so predictable.

"Motherwort" reads, to any English speaker, as a herb for mothers. It sounds nurturing. Add the well-documented postpartum tradition — the herb genuinely was given to women after childbirth — and the natural inference is that motherwort is a pregnancy-friendly herb. It is not. The tradition is for labour and after delivery, and the properties that made it useful then are precisely the properties that rule it out during pregnancy.

The other names make the point more clearly than the common one does. "Mother" here means the womb: in older English medical writing "the mother" was a term for the uterus, so motherwort meant the womb-herb, not the mother's herb. The old folk name throw-wort refers to the throes of labour. Neither name promises safety in pregnancy; both point at the uterus.

Now put that together with why people arrive at this plant. Palpitations, breathlessness and anxiety are all common in pregnancy. Motherwort is widely recommended online for palpitations and anxiety. The name reassures. That is a complete, foreseeable route by which a pregnant woman takes a contraindicated uterine stimulant while trying to settle her heart — which is why the warning appears on every motherwort page in this section rather than being tucked into one.

Motherwort is one of the clearest examples on this site of a common name implying a safety profile the plant does not have. Comfrey, pennyroyal and blue cohosh are others where the folk name or reputation understates the risk. The general lesson holds: a friendly name is not safety data.

Back to Table of Contents

Breastfeeding

Avoid while breastfeeding. The reason here is plainer still: there is no meaningful safety data. Nobody has established whether motherwort's constituents pass into breast milk, in what quantity, or with what effect on an infant.

That the traditional postpartum use existed does not resolve this. It was practised in a setting with a very different risk calculus, no way to detect a subtle effect on a newborn, and no expectation of the evidence standard now applied to anything a nursing mother takes. Two specific concerns are worth naming: the herb's sedative activity, which is the action with the most preclinical support, would be unwelcome in an infant; and the bitter diterpenes could plausibly affect the taste of milk and feeding.

For any question about a substance during breastfeeding, the standard reference is LactMed, the US National Library of Medicine's drugs-and-lactation database, hosted on NCBI Bookshelf.

Back to Table of Contents

Why This Population Is the Wrong One

Most herb-interaction discussions are abstract because the overlap between herb users and drug users is modest. Motherwort is the opposite case, and it is worth being explicit about why.

The herb's headline traditional indication is palpitations and cardiac symptoms. Who has those? Disproportionately: people over sixty, people with hypertension, people with diagnosed arrhythmias, people after a heart attack, people with heart failure. That population is heavily medicated, and medicated specifically with the drug classes motherwort might plausibly interact with — rate-slowing drugs, antihypertensives, antiarrhythmics, digoxin, anticoagulants.

Two consequences follow.

First, the interaction probability is not low even if each individual interaction is uncertain. If a large share of users take at least one relevant drug, then even modest per-interaction risk aggregates into something real.

Second, the consequences are asymmetric. An interaction between a herb and, say, a topical eczema treatment is an inconvenience. An interaction that pushes a heart rate too low, destabilises an antiarrhythmic, or adds to an anticoagulant produces bradycardia, arrhythmia, or bleeding. These are the failure modes people are hospitalised for.

The general framework for this reasoning is set out in the cardiology literature — Tachjian, Maria and Jahangir's review of herbal product use and potential interactions in patients with cardiovascular disease, published in the Journal of the American College of Cardiology in 2010, is the standard reference, and the broader picture appears in Izzo and Ernst's systematic review of interactions between herbal medicines and prescribed drugs in Drugs in 2009. Neither is about motherwort specifically. Both explain why a cardiac patient is the wrong person to be experimenting on.

Back to Table of Contents

Beta-Blockers and Other Rate-Slowing Drugs

Tier: theoretical, with preclinical support. Practical advice: do not combine without your prescriber's input.

Drugs involved: beta-blockers (bisoprolol, metoprolol, atenolol, propranolol, carvedilol and others), rate-limiting calcium channel blockers (diltiazem, verapamil), ivabradine, and digoxin in its rate-controlling role.

The mechanistic case for concern is the most substantive of any motherwort interaction. Ritter and colleagues, in Planta Medica in 2010, reported that primary and refined extracts of Leonurus cardiaca slowed rate and altered electrophysiology in isolated cardiac preparations. Miłkowska-Leyck and colleagues, in the Journal of Ethnopharmacology in 2002, reported that the isolated glycoside lavandulifolioside reduced heart rate and blood pressure in animals. Both findings are exactly what would predict additive bradycardia on top of a rate-slowing drug.

What is missing is the human half. Nobody has measured what happens to heart rate in a person on bisoprolol who starts motherwort tincture, and there are no published case reports of symptomatic bradycardia from the combination. Calling this "documented" would be false.

But the practical position does not soften. Bradycardia matters because a heart rate that falls too low produces fatigue, dizziness, exercise intolerance and, at the extreme, syncope — and syncope in an older person means falls and fractures. Many people on beta-blockers already sit in the fifties. There is no room for an unquantified additional rate-slowing agent, particularly one whose dose you cannot know because tincture concentrations vary several-fold between products.

If you take a rate-slowing drug and want to try motherwort: raise it with your prescriber first, and if you proceed, know your resting pulse before you start and check it. Dizziness, unusual fatigue, breathlessness on exertion or near-fainting after starting are reasons to stop and seek advice.

Back to Table of Contents

Digoxin and Antiarrhythmic Drugs

Tier: theoretical. Practical advice: do not combine.

Drugs involved: digoxin; antiarrhythmics including amiodarone, flecainide, sotalol, propafenone, dronedarone.

The argument here is about margins rather than mechanism. Digoxin has one of the narrowest therapeutic windows in common use — the gap between an effective level and a toxic one is small, blood levels are monitored for exactly that reason, and digoxin toxicity presents with nausea, visual disturbance, confusion and, characteristically, arrhythmias. Antiarrhythmic drugs share the same uncomfortable property: they are given to suppress rhythm disturbances and, at the wrong concentration or in the wrong electrical environment, they cause them.

Into that environment, adding a botanical extract with demonstrated electrophysiological activity in cardiac tissue, at an unknown dose, with unknown pharmacokinetics, is a poor trade. There is no potential benefit large enough to justify it, because motherwort has no demonstrated antiarrhythmic efficacy in humans in the first place.

Two secondary considerations. Motherwort has not been characterised for effects on P-glycoprotein or the cytochrome P450 enzymes that govern the handling of many of these drugs, so transport- and metabolism-level interactions cannot be ruled out either way. And electrolytes matter enormously to antiarrhythmic safety — low potassium and low magnesium both promote arrhythmia — so anything causing diarrhoea, which bitter herbs can, has an indirect route to trouble. See Potassium and Arrhythmia and Magnesium and Palpitations.

Back to Table of Contents

Blood-Pressure Medication

Tier: theoretical, with preclinical and weak human support. Practical advice: check with your prescriber; monitor if you proceed.

Drugs involved: ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, alpha-blockers, beta-blockers.

This is the one interaction with any human data at all, and the data are weak. The small open-label study by Shikov and colleagues in Phytotherapy Research in 2011 reported modest blood-pressure reductions with a Leonurus cardiaca oil extract in patients with hypertension, anxiety and sleep disturbance — with no placebo group, so the effect may not be real. Lavandulifolioside lowered blood pressure in animals.

Taken together, a mild additive antihypertensive effect is plausible. Some readers may see that as a benefit rather than a risk. Two cautions apply. Additive lowering matters most in people already near the floor — older people, those on several agents, those prone to postural drops — where the result is dizziness on standing and a fall risk. And a herb whose blood-pressure effect is unquantified is a poor way to manage a condition where the treatment target is a number: if your pressure improves, neither you nor your doctor can tell how much came from the herb, which complicates any later medication change.

If you take antihypertensives and use motherwort, measure your pressure at home, keep a record, and share it. See Hypertension, and Hawthorn and Blood Pressure for a related herb with more trial data.

Back to Table of Contents

Sedatives, Alcohol and Other Calming Herbs

Tier: preclinical plus pharmacological class effect — the best-supported interaction motherwort has. Practical advice: expect additive drowsiness; take care with driving.

Substances involved: benzodiazepines (diazepam, lorazepam, alprazolam), Z-drugs (zopiclone, zolpidem), sedating antihistamines, opioids, some antidepressants and antipsychotics, gabapentin and pregabalin, alcohol, and other sedative herbs including valerian, passionflower, lemon balm, chamomile, hops and kava.

This one rests on more than analogy. Sedative activity is the action with the most consistent preclinical support in L. cardiaca: lavandulifolioside was sedative in animals (Miłkowska-Leyck and colleagues, 2002), modified dry extracts showed psychotropic activity in animal behavioural testing (Koshovyi and colleagues, Plants, 2021), and the analgesic testing reported by Rezaee-Asl and colleagues in 2014 is consistent with central depressant activity. Additive sedation between agents that each depress the central nervous system is a general and reliable pharmacological principle.

Practical consequences: more drowsiness than expected, impaired coordination and reaction time, and impaired judgement about how impaired you are — which is the reason this matters for driving and machinery. In older adults, added sedation also raises the risk of falls and worsens confusion.

Two notes for herb users specifically. Multi-herb "calm" or "sleep" formulas frequently combine motherwort with valerian, passionflower and hops, so you may be stacking several sedatives without noticing. And alcohol counts — including the alcohol in the tincture itself, which is minor at normal doses but not zero.

Back to Table of Contents

Antiplatelet and Anticoagulant Drugs

Tier: theoretical. Practical advice: caution, and tell your anticoagulation clinic.

Drugs involved: warfarin, direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran), aspirin, clopidogrel, ticagrelor, prasugrel, and heparins.

The basis for the caution is general rather than specific. Motherwort's constituents include a substantial flavonoid fraction, and various plant flavonoids affect platelet function in laboratory preparations. There is no controlled human study of motherwort and platelet function, no study of motherwort and the international normalised ratio in warfarin users, and no published case series of bleeding. This is genuinely theoretical.

The reason to take a theoretical concern seriously here is again the population. Atrial fibrillation is a common cause of the palpitations that lead people to motherwort, and most people with atrial fibrillation above a risk threshold are anticoagulated. So the overlap between motherwort users and anticoagulant users is substantial by construction. Bleeding on an anticoagulant is not a minor adverse event: gastrointestinal and intracranial bleeding are the reasons these drugs are managed carefully.

Practical steps: tell your anticoagulation clinic or pharmacist about any herbal product, including this one — they are used to the question and they would much rather know. If you take warfarin, do not start or stop any botanical between monitoring appointments without mentioning it. And note the historical association of very large motherwort doses with uterine bleeding, which sits in the same general territory.

Back to Table of Contents

Direct Side Effects

Setting interactions aside, the herb itself has a modest and mostly predictable side-effect profile.

Back to Table of Contents

Product Quality and Species Substitution

A safety page has to cover the product as well as the plant, because herbal supplements are regulated far more loosely than medicines in most countries.

Species substitution is the specific issue for motherwort. Two plants share the common name: European Leonurus cardiaca and East Asian Leonurus japonicus (yi mu cao). They differ chemically — the comparative quantification of the marker alkaloid stachydrine in both species by Kuchta and colleagues in Fitoterapia in 2014 documents this — and the alkaloid leonurine, which carries most of the genus's dramatic pharmacology, is chiefly a japonicus constituent, present in European cardiaca at low, variable and analytically disputed levels. Supplement marketing routinely attributes leonurine pharmacology to European motherwort. Buy products that name the species on the label.

Other quality points that bear on safety:

Back to Table of Contents

Who Should Avoid It Entirely

Back to Table of Contents

How to Raise It With Your Doctor

Many people do not mention herbal products to their doctor, often because they expect dismissal. It is worth mentioning anyway, and a few things make the conversation go better.

Back to Table of Contents

Evidence Tiers at a Glance

Back to Table of Contents

Key Research Papers

Links are PubMed topic searches, so they return the current literature rather than one frozen record.

  1. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. Journal of the American College of Cardiology, 2010. The standard cardiology reference for why this patient group is the wrong one for unquantified botanicals. PubMed: herbal products and cardiovascular interactions
  2. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 2009. The broad systematic picture of herb-drug interaction evidence and its gaps. PubMed: herb-drug interaction systematic review
  3. Ritter M, Melichar K, Strahler S, et al. Cardiac and electrophysiological effects of primary and refined extracts from Leonurus cardiaca L. Planta Medica, 2010. The isolated-tissue basis for the rate-slowing interaction concern. PubMed: Leonurus cardiaca cardiac electrophysiology
  4. Miłkowska-Leyck K, Filipek B, Strzelecka H. Pharmacological effects of lavandulifolioside from Leonurus cardiaca. Journal of Ethnopharmacology, 2002. Reduced heart rate, lowered blood pressure and sedation in animals — the basis for three of the interaction concerns at once. PubMed: lavandulifolioside pharmacology
  5. Shikov AN, Pozharitskaya ON, Makarov VG, et al. Effect of Leonurus cardiaca oil extract in patients with arterial hypertension accompanied by anxiety and sleep disorders. Phytotherapy Research, 2011. The only human blood-pressure signal; small, open-label, no placebo arm. PubMed: Leonurus cardiaca and blood pressure
  6. Koshovyi O, Raal A, Kireyev I, et al. Phytochemical and psychotropic research of motherwort (Leonurus cardiaca L.) modified dry extracts. Plants, 2021. Whole-extract sedative and psychotropic activity in animals — the sedation-interaction basis. PubMed: Leonurus cardiaca psychotropic extracts
  7. Rezaee-Asl M, Sabour M, Nikoui V, et al. The study of analgesic effects of Leonurus cardiaca L. in mice by formalin, tail flick and hot plate tests. International Scholarly Research Notices, 2014. Animal work consistent with central depressant activity. PubMed: Leonurus cardiaca analgesic testing
  8. Wojtyniak K, Szymański M, Matławska I. Leonurus cardiaca L. (motherwort): a review of its phytochemistry and pharmacology. Phytotherapy Research, 2013. Includes the traditional contraindications and the state of the safety literature. PubMed: Leonurus cardiaca review
  9. Fierascu RC, Fierascu I, Ortan A, et al. Leonurus cardiaca L. as a source of bioactive compounds: an update of the European Medicines Agency assessment report. BioMed Research International, 2019. The link between the herb's chemistry and Europe's formal safety and traditional-use assessment. PubMed: Leonurus cardiaca EMA assessment
  10. Kuchta K, Ortwein J, Hennig L, et al. Direct quantification of stachydrine in Leonurus japonicus and L. cardiaca by quantitative nuclear magnetic resonance. Fitoterapia, 2014. The analytical basis for the species-substitution warning. PubMed: stachydrine in Leonurus species
  11. Literature on herbal medicine use in pregnancy and its safety, including reviews of emmenagogue and uterine-stimulant botanicals. The general framework behind the pregnancy contraindication. PubMed: herbal medicines in pregnancy
  12. Literature on herbal supplement use and perioperative risk, including bleeding and sedation, which underlies the stop-before-surgery advice. PubMed: herbal supplements and surgery
  13. Literature on adulteration, misidentification and contamination in botanical products, which is why naming the species on the label matters. PubMed: botanical adulteration and authentication
  14. Broader current searches: PubMed: Leonurus cardiaca safety and PubMed: motherwort drug interaction.

External Resources

Back to Table of Contents

Connections


Safety Note and Disclaimer

This page is health education, not medical advice, and it cannot substitute for a review of your own medication list by a pharmacist or doctor. Motherwort must be avoided in pregnancy — it is a traditional uterine stimulant and emmenagogue, and its common name misleadingly suggests it is a pregnancy-friendly herb. It should also be avoided while trying to conceive and while breastfeeding. Do not add motherwort to beta-blockers, other rate-slowing drugs, antihypertensives, digoxin, antiarrhythmics, sedatives, antiplatelet drugs or anticoagulants without speaking to your prescriber first, and never stop or reduce prescribed cardiac medication in order to use a herb. Most of the interactions described here are theoretical or preclinical rather than documented in case reports — but in a population this heavily medicated, with arrhythmia and bleeding as the failure modes, that uncertainty is a reason for caution rather than reassurance. Palpitations that have never been evaluated need an ECG, not a herb: seek urgent care for palpitations with chest pain, breathlessness, fainting or near-fainting.

Back to Table of Contents